We can't find the internet
Attempting to reconnect
14032.1;10 PFLS-LS
Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)
Zusammenfassung
Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)
Weitere Texte
Abstract
The proposed CTI project aims to develop PI3K/mTOR kinase inhibitors as a new generation of drugs for the treatment of solid tumors such as pancreatic cancer. The designed approach allows discovery and development of lipid-modifying enzyme inhibitors. The methodology and the products complement the existing PIQUR technology portfolio, and open a new branch of commercial opportunities. The project is expected to support current PIQUR activities by identifying a best-in-class clinical candidate, which in comparison with the competitor compounds of same mode of action, has a balanced dual PI3K/mTOR inhibition and improved pharmacological properties, providing optimal therapies, tailored to the unique needs of solid tumors.
Beteiligte
Matthias Wymann
Kontaktperson
matthias.wymann@unibas.ch
Universität Basel Matthias Wymann Mattenstrasse 28 4058 Basel BS CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2012-05-31
- Enddatum
- 2014-10-22
- Bewilligte Gesamtkosten
- CHF 581283.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Nicht aufteilbare / nicht zuteilbare Forschung
Forschungsdisziplinen
- P004 Biochemistry, Metabolism 100.0%